<DOC>
	<DOCNO>NCT02093429</DOCNO>
	<brief_summary>The study design include 3-dose randomization phase determine effective dos INCB047986 patient myelodysplastic syndrome ( MDS ) refractory unlikely respond erythropoiesis-stimulating agent ( ESAs ) follow extension phase .</brief_summary>
	<brief_title>Randomized Open-Label Study INCB047986 Subjects With Primary Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>After 50 % subject complete 16 week treatment ( 10 subject dose group ) , plan interim analysis conduct determine , , dose level warrant investigation base observe least 3 response hematologic improvement erythrocyte ( HI-E ) adequate safety tolerability . Subjects meet response criterion erythroid improvement may treat ESA combination INCB047986 additional 16 week . The study comprise : Screening : 4 week . Treatment Phase 1 : least 16 week INCB047986 . Treatment Phase 2 : least 8 16 week INCB047986 combination ESA fail treatment Phase 1 . Extension Phase : Subjects receive benefit either therapy may continue indefinitely study terminate . Follow-Up : 30 ( ± 7 ) day last dose INCB047986 take .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Subjects 18 year age old . Subjects must diagnose MDS accord World Health Organization ( WHO ) classification de novo primary MDS ( Vardiman et al 2009 ) . Subjects require RBC transfusion either refractory unlikely respond ESA therapy meet one follow criterion : ESA failure define improvement Hgb least 1.5 g/dL 8 week least 40,000 IU per week EPO ( equivalent ) . Have serum erythropoietin ( EPO ) ≥ 500 IU Hgb level &lt; 10.0 g/dL . Transfusion dependence define require least 4 unit pack red blood cell ( RBCs ) Hgb &lt; 9 g/dL 8 week prior screen . Subjects may receive hypomethylating agent immunosuppressive therapy MDS prior study . Subjects high risk transformation acute leukemia evidence poor karyotype peripheral blood blast &gt; 10 % . Subjects severely compromised bone marrow function evidence trilineage cytopenia anemia ( Hgb &lt; 10 g/L , platelet &lt; 100 × 109/L , absolute neutrophil count ( ANC ) &lt; 1.8 × 109/L ) . Subjects harbor 5q deletion chromosomal aberration . Subjects chronic myelomonocytic leukemia ( CMML ) . Women pregnant breastfeeding , men woman comply requirement avoid father child become pregnant , respectively . Subjects impair liver function , end stage renal disease dialysis , clinically significant concurrent infection require therapy . Subjects unstable cardiac function . Invasive malignancy previous 2 year except treat basal squamous carcinoma skin , completely resect intraepithelial carcinoma cervix , Stage 1 2 treated prostate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>